Breast Cancer Articles

Expert Discusses Lymphedema Treatment and Challenges in Breast Cancer
Oscar J. Manrique, MD, discusses the current treatments for patients with lymphedema who have breast cancer and the challenges that remain in this space.
Less Invasive Techniques Transform Surgical Management of Breast Cancer
Judy C. Boughey, MD, discusses the surgical management of the axilla in patients with node-positive breast cancer and less invasive approaches for disease management.
Expert Addresses Controversies in Management of HR+ Early-Stage Breast Cancer
Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events. 
CDK4/6 Inhibitors Are Transforming Treatment in HR+ Breast Cancer
Terry L. Evans, MD, discusses the impact of CDK4/6 inhibitors in the metastatic breast cancer space and challenges that still need to be addressed.
TAILORx Analysis Underscores Racial Disparity in Breast Cancer Outcomes
African-American patients with early breast cancer had worse outcomes than Caucasian patients following adjuvant therapy, despite having a similar risk of recurrence and receiving similar types of therapy, according to subgroup analysis of the phase III TAILORx trial.
TAILORx Update Shows Different PRO Profiles for Chemo, Endocrine Therapy for Breast Cancer
Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.
CAR T-Cell Therapy Shows Early Potential in TNBC
Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.
Telephone-Based Lifestyle Interventions Improved Breast Cancer Outcomes
Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.
Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer
The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.
Breast Cancer Surgery Choice May Affect Quality of Life in Younger Patients
Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.
Publication Bottom Border
Border Publication